Ductal Carcinoma In Situ: The Whole Truth
- 1 February 2018
- journal article
- review article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 210 (2), 246-255
- https://doi.org/10.2214/ajr.17.18778
Abstract
OBJECTIVE. Ductal carcinoma in situ (DCIS) is a noninvasive malignant breast disease traditionally described as a precursor lesion to invasive breast cancer. With screening mammography, DCIS now accounts for approximately 20% of newly diagnosed cancer cases. DCIS is not well understood because of its heterogeneous nature. CONCLUSION. Studies have aimed to assess prognostic factors to characterize its risk of invasive potential; however, there still remains a lack of uniformity in workup and treatment. We summarize current knowledge of DCIS and the ongoing controversies.Keywords
This publication has 93 references indexed in Scilit:
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the BreastJNCI Journal of the National Cancer Institute, 2013
- Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24Journal of Clinical Oncology, 2012
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCISJNCI Journal of the National Cancer Institute, 2011
- Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and OutcomesJNCI Journal of the National Cancer Institute, 2010
- Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breastOncogene, 2010
- Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2009
- The transition from ductal carcinoma in situto invasive breast cancer: the other side of the coinBreast Cancer Research, 2009
- The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situWorld Journal of Surgical Oncology, 2008
- COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situBMC Cancer, 2008
- 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screeningThe Lancet, 1999